Professor Yongho Kim of 嘉泉大学医学院 and CEO of RudaCure Inc. was recently selected as a participant in the 科学技术信息通信部's 'Platform Core Technology Development Project for Responding to New and Variant Infectious Diseases.' The project involves 嘉泉大学 as well as 首尔大学, Chung-Ang University, Sungkyunkwan University, and others.
This project was newly established this year to strengthen national infectious disease response capabilities, protect public health, improve medical welfare, and secure international competitiveness. Led by the 科学技术信息通信部, it aims to build an infectious disease technology platform through the development of core and gap technologies in respective fields.
Professor Kim will conduct research for four years starting this year on the theme of "Development of Viroporin (viral 离子通道 protein) target inhibition technology based on 离子通道 function verification systems," and will receive approximately KRW 2 billion in government research funding over the four-year period.
Professor Kim is an expert in 离子通道s and conducts clinical and 临床前 research together with faculty at the Gachon Pain Research Institute within 嘉泉大学医学院.